Last reviewed · How we verify

NCT02950220

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed Phase 1 Last updated 30 July 2019
What this trial tests

Phase 1 trial testing Ibrutinib in B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma in 2 participants. Completed in 3 January 2019.

Timeline
12 January 2017
Primary endpoint
19 November 2018
3 January 2019

Quick facts

Lead sponsorKami Maddocks
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment2
Start date12 January 2017
Primary completion19 November 2018
Estimated completion3 January 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kami Maddocks — full company profile →

Who can join

18 and older, any sex, with B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma or Grade 1 Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/Ib trial studies the side effects and best dose of ibrutinib when given together with pembrolizumab and to see how well they work in treating patients with non-Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Given pembrolizumab and ibrutinib may work better in treating patients with non-Hodgkin lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
  2. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
    Merryman RW, Armand P, Wright KT, Rodig SJ. · · 2017 · cited 87× · PMID 29296917 · DOI 10.1182/bloodadvances.2017012534
  3. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
    Cao Y, Xie L, Shi F, Tang M, et al · · 2021 · cited 86× · PMID 33436584 · DOI 10.1038/s41392-020-00376-4
  4. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Zhang J, Zhang J, Medeiros LJ, Young KH. · · 2018 · cited 65× · PMID 30250823 · DOI 10.3389/fonc.2018.00351
  5. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
    Hatic H, Sampat D, Goyal G. · · 2021 · cited 50× · PMID 34277837 · DOI 10.21037/atm-20-6833
  6. Immune checkpoint blockade for hematologic malignancies: a review.
    Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. · · 2017 · cited 48× · PMID 28529947 · DOI 10.21037/sci.2017.03.04
  7. Immune checkpoint inhibitors in the treatment of virus-associated cancers.
    Gao P, Lazare C, Cao C, Meng Y, et al · · 2019 · cited 47× · PMID 31182108 · DOI 10.1186/s13045-019-0743-4
  8. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.
    Lees C, Keane C, Gandhi MK, Gunawardana J. · · 2019 · cited 44× · PMID 30740662 · DOI 10.1111/bjh.15778

Verify or expand the search:

Other trials of Ibrutinib

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02950220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing